Immunovant, Inc. (IMVT)

NEUTRAL

HealthcareBiotechnologyUnited States

Fundamental

मूल्य

$43.31

मार्केट कैप

$9.01B

Yahoo Finance TradingView समाचार वेबसाइट

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

31/3/2026 को समाप्त वित्त वर्ष

शुद्ध आय

$-506M

31/3/2026 को समाप्त वित्त वर्ष

Free Cash Flow

$-407M

कुल इक्विटी

$853M

कुल देनदारियाँ

$104M

Current Ratio

7.27

Interest Coverage

Debt/EBITDA

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

Pre-revenueउचित मूल्यांकित

Fair Value

$48.88

वर्तमान मूल्य

$43.31

Margin of Safety

+11.4%

Fair Value सीमा

$46.43 - $51.32

अनुमान विधियाँ

Analyst price target:$48.88

Discounted cash flow (DCF):Not applicable to this type of company

Earnings multiple (P/E):Not applicable to this type of company

Graham growth formula:Not applicable to this type of company

Earnings power value (EPV):Not applicable to this type of company

Justified P/B:Not applicable to this type of company

Dividend discount (Gordon):Not applicable to this type of company

P/FFO, funds from operations:Not applicable to this type of company

Mid-cycle earnings:Not applicable to this type of company

Revenue multiple:Not enough data to compute it

विश्लेषक सहमति:दृढ़ खरीदें (18B / 4H / 0S)

अंतिम Earnings सरप्राइज़:-19.48%

मूल्यांकन मेट्रिक्स

P/E Ratio

ROE

-59.3%

P/B Ratio

12.17

P/FCF

Gross Margin

ROIC

लाभप्रदता Radar

Value Creation (Economic Moat)

ROIC

WACC

9.1%

ROIC − WACC

Fundamental विश्लेषण मानदंड

पास (5)

Price CAGR 15.82%
Debt/Equity ratio
Current Ratio
Low reliance on intangibles
Analyst Consensus 82% Buy

फेल (9)

EPS shows upward trend
P/B Ratio 12.17
Positive Free Cash Flow
Return on Tangible Assets
DCF valuation (Unknown)
ROE -69.6%
Earnings Surprise avg -5.5%
Share Dilution 20.4%
Piotroski F-Score 2/9

अनुपलब्ध (13)

ROIC NaN%
Gross Margin NaN%
P/FCF NaN
Dividend Payout NaN%
Operating Margin NaN%
CapEx intensity
Interest Coverage
Debt/EBITDA
Price below Graham Number
Revenue Growth 5Y (Finnhub)
PEG Ratio (need PE > 0 and growth > 0)
Earnings Quality (OCF/Net Income)
Net Margin Trend (invalid data)

Piotroski F-Score

2/9

गंभीर वित्तीय चिंताएं

score

criteria

Earnings गुणवत्ता

निम्न गुणवत्ता: accounting की जांच करें

शेयर Dilution

20.4%

नए शेयर जारी कर रही है, स्वामित्व को कम कर रही है

प्रशासन

कार्यकारी टीम

नाम	पद	आयु
Dr. Frank M. Torti M.B.A., M.D.	Executive Chairperson of the Board	46
Dr. Eric Venker M.D., Pharm.D.	CEO & Director	38
Mr. Tiago M. Girao CPA	Chief Financial Officer	46
Ms. Melanie Gloria B.S.N.	Chief Operating Officer	47
Dr. Jay S. Stout M.S., Ph.D.	Chief Technology Officer	62
Mr. Christopher A. Van Tuyl Esq., J.D.	Chief Legal Officer & Corporate Secretary	50
Ms. Christine Blodgett	Senior Vice President of Human Resources	-
Ms. Becky Merlina	Senior VP & Global Head of Quality	-
Ms. Yan Zheng M.S., Ph.D.	Senior Vice President of Biostatistics, Programming & Data Management	-
Ms. Sheetal Patel M.B.A., M.D., M.S.	Senior Vice President of Clinical Development	-

Audit जोखिम

बोर्ड जोखिम

मुआवजा जोखिम

शेयरधारक अधिकार जोखिम

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

Latest News

Recent headlines for IMVT, sourced from Markets Gazette.

3/15/2026POSITIVE
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
A healthcare hedge fund has significantly increased its stake in Immunovant Inc., acquiring an additional $24.5 million worth of stock. Immunovant is a clinical-stage biopharmaceutical company focused on developing antibody therapies for autoimmune diseases. Its lead candidate is currently undergoing Phase II trials. This substantial investment by a specialized healthcare fund suggests strong conviction in the company's pipeline and future prospects. For investors, this move could signal positive upcoming developments or a favorable risk-reward profile for Immunovant's stock.
3/11/2026POSITIVE
Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish
Immunovant Inc. (IMVT) experienced a significant surge, with its stock price climbing 30%. This upward momentum comes despite a notable insider trimming their stake by $3 million. The company, which focuses on antibody therapies for autoimmune diseases, has seen its lead candidate advance through clinical trials. This progress in its drug development pipeline is a key driver for investor optimism, suggesting potential future revenue streams and market expansion. The stock's performance indicates strong market confidence in Immunovant's therapeutic pipeline and its long-term growth prospects, outweighing the impact of the insider's partial divestment.

via Markets Gazette